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abstract
Aims. galectin-3 is an emerging biomarker which has been studied in relatively small heart failure (Hf) cohorts with 
predominantly systolic Hf. We studied the prognostic value of base-line galectin-3 in a large Hf cohort, with preserved 
and reduced left ventricular ejection fraction (lvef), and compared this to other biomarkers.
Methods. We studied 592 Hf patients who had been hospitalized for Hf and were followed for 18 months. The primary 
end-point was a composite of all-cause mortality and Hf hospitalization.
Results. A doubling of galectin-3 levels was associated with a hazard ratio (HR) of 1.97 (1.62–2.42) for the primary out-
come (P  0.001). After correction for age, gender, BnP, egfR, and diabetes the HR was 1.38 (1.07–1.78; P  0.015). 
galectin-3 levels were correlated with higher il-6 and CRP levels (P  0.002). Changes of galectin-3 levels after 6 months 
did not add prognostic information to the base-line value (n  291); however, combining plasma galectin-3 and BnP 
levels increased prognostic value over either biomarker alone (RoC analysis, P  0.05). The predictive value of galectin-3 
was stronger in patients with preserved lvef (n  114) compared to patients with reduced lvef (P  0.001).
Conclusions. galectin-3 is an independent marker for outcome in Hf and appears to be particularly useful in Hf patients 
with preserved lvef.
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introduction
Although progress has been made in early diagnosis 
and risk stratification of heart failure (Hf), we are 
still short of tools to detect the disease early and to 
predict prognosis (1). several biomarkers are used 
for diagnosis and prognosis of Hf patients. Recently, 
galectin-3 has been proposed as a novel biomarker 
(2). galectin-3 is secreted by activated macrophages 
and modulates several physiological and pathologi-
cal processes (3) that contribute to Hf, including 
inflammation  and  fibrosis.  The  up-regulation  of 
myocardial galectin-3 has initially been demonstrated 
in a rat model of Hf-prone hypertensive hearts (4). 
subsequently, elevated levels of plasma galectin-3 in 
patients with acute (5) and chronic Hf (6–8) were 
consistently associated with adverse outcome.
However,  the  studies  published  thus  far  only 
comprised  several  hundred  patients.  Clinical  and 
biochemical  correlates  of  galectin-3  are  currently 
largely unknown. furthermore, no data have been 
published  on  whether  galectin-3  is  a  useful  bio-
marker in patients with Hf with preserved ejection 
fraction  (HfPef)  in  comparison  with  Hf  with 
reduced ejection fraction (HfRef). A recent anal-
ysis  from  the  ProBnP  investigation  of  dyspnea   
in the emergency department (PRide) (5) study 
suggested  that  galectin-3  particularly  correlates 
with  echocardiographic  indices  of  diastolic  func-
tion (9). finally, the question as to whether serial 
measurements of galectin-3 have incremental value 
over  base-line  measurements  alone  has  not  been 
addressed.
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Therefore, we investigated the predictive value   
of galectin-3 in Hf due to HfRef or HfPef and 
compared  this  to  an  established  biomarker,  nT-
pro-brain natriuretic peptide (nT-proBnP), and to 
several cytokines that have been associated with Hf 
and that have been pathophysiologically related to 
galectin-3,  including  il-6  and  hsCRP.  finally,  we 
evaluated if a follow-up measurement of galectin-3 
taken after 6 months would further strengthen the 
value of galectin-3 in predicting outcome in Hf.
Methods
Study design and outcome parameters
This  is  a  prospectively  designed  substudy  of  the 
Coordinating study evaluating outcomes of Advising 
and Counseling in Heart failure (CoACH) trial. 
The  design  and  outcomes  of  the  CoACH  trial 
(nCT98675639)  have  been  published  (10,11). 
Briefly,  patients  were  included  to  participate  in  a 
prospective randomized disease management study. 
A total of 1,023 patients were included. Plasma for 
galectin-3  determination  (and  other  biomarkers) 
was  available  from  592  patients  during  the  index 
admission, and these are considered in the current 
subanalysis. samples were collected just before dis-
charge, when patients were stabilized after an acute 
Hf  admission.  mean  follow-up  was  18  months. 
demographic and clinical data were collected during 
index admission from the medical charts. An addi-
tional plasma sample was taken after 6 months in 
291 subjects during their visit to the outpatient depart-
ment. To identify HfPef, we chose a cut-off point 
of left ventricular ejection fraction (lvef)  40%, 
which  is  the  same  cut-off  point  as  used  in  the 
CHARm trial (12).
for  the  current  analysis,  we  used  the  primary 
outcome of CoACH: time to first rehospitalization 
for heart failure or death. Hospitalization due to Hf 
was defined as an unplanned overnight stay in the 
hospital due to worsening Hf. Patients had to have 
typical symptoms and signs of Hf, using standard 
criteria. All events were evaluated and adjudicated 
by an independent end-point committee. This study 
complies  with  the  declaration  of  Helsinki,  local 
medical ethics committees approved the study, and 
all patients provided written informed consent.
Measurement of galectin-3
The galectin-3 assay is an enzyme-linked immuno-
sorbent assay (elisA) developed by Bg medicine 
(Bg  medicine,  inc., Waltham,  usA). This  assay 
quantitatively measures the concentration of human 
galectin-3  levels  in  edTA  plasma. This  assay  has 
high sensitivity (lower limit of detection 1.13 ng/ml) 
and  exhibits  no  cross-reactivity  with  collagens  or 
other  members  of  the  galectin  family.  Commonly 
used  Hf  medication  like  angiotensin-converting 
enzyme (ACe) inhibitors, beta-blockers, spironolac-
tone, furosemide, acetylsalicylic acid, warfarin, cou-
marines, and digoxin have no interference with the 
assay (13).
Biochemical analysis of other of cytokines
levels of cytokines (vascular endothelial growth fac-
tor (vegf), interleukin-6 (il-6), C-reactive protein 
(CRP), and transforming growth factor-b1 (Tgf-
b1)) in plasma samples were measured using search-
light®  Proteome  Arrays  (Aushon  Biosystems, 
Billerica,  mA,  usA). The  searchlight  Proteome 
Array is a quantitative multiplexed sandwich elisA 
containing  up  to  12  different  capture  antibodies 
spotted  on  the  bottom  of  a  96-well  polystyrene 
microtiter plate. each antibody captures a specific 
protein present in the standards and samples added 
to the plate. The bound proteins are detected with a 
biotinylated  detection  antibody,  followed  by  the 
addition  of  streptavidin–horse-radish  peroxidase 
(HRP), and lastly a chemiluminescent substrate. The 
luminescent  signal  produced  from  the  HRP-cata-
lyzed  oxidation  of  the  substrate  was  measured  by 
imaging  the  plate  using  the  searchlight  imaging 
system  which  is  a  cooled  charge-coupled  device 
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(CCd)  camera.  The  data  were  analyzed  using 
searchlight Array Analyst software. The amount of 
luminescent signal produced is proportional to the 
amount of each protein present in the original stan-
dard or sample. Concentrations were extrapolated 
using a standard curve.
Statistical analysis
We divided galectin-3 levels (ng/ml) in quartiles (1st 
quartile:  5.0–15.2;  2nd  quartile:  15.2–20.0;  3rd 
quartile 20.0–25.9; 4th quartile 25.9–66.6). Base-line 
demographics are given in means  standard devia-
tion  (sd)  or  as  medians  with  interquartile  ranges 
(iQR) when variables were non-normally distributed.
We conducted univariable analysis to evaluate the 
predictive value of galectin-3 (and other markers of 
prognosis) for the development of the primary out-
come (composite of all-cause mortality and hospital-
ization due to Hf).  Then we conducted Cox regression 
analysis and stepwise included known predictors of 
prognosis to evaluate whether galectin-3 has indepen-
dent prognostic value. if a factor modulated the pre-
dictive strength of galectin-3, we tested if interaction 
existed between the factors. We used receiver-operat-
ing  characteristic  (RoC)  methodology  to  discrimi-
nate the predictive performance of different biomarker 
settings adjusted for age and sex. P values  0.05 
denote statistically significant differences.
results
Study population
Base-line characteristics of the 592 patients in this 
subanalysis  were  comparable  to  those  of  the  total 
CoACH cohort (n  1,023; data not shown). mean 
age of the study population was 72  12 years, and 
65% were male patients. Half of the patients were   
in  new york  Heart Association  (nyHA)  class  iii   
and iv, the other half were in nyHA class ii. lvef 
was  recorded  mostly  by  echocardiography:  mean 
lvef was 0.33  0.15; 485 subjects had a lvef  
0.40, and 107 patients had a lvef  0.40. mean 
estimated  glomerular  filtration  rate  (egfR)  was   
55 ml/min/1.73 m2, median brain natriuretic pep-
tide (BnP) value was 448 pg/ml, and patients were 
on  standard  medication  for  Hf,  including  ACe 
inhibitors, beta-blockers, and diuretics.
Base-line characteristics of patients stratified to 
galectin-3 levels (Table I)
Table i shows the base-line characteristics of patients 
according to quartiles of plasma galectin-3 levels. 
Patients  with  higher  galectin-3  levels  were  older   
(P  for  trend    0.001)  and  more  often  female   
(P  0.023). Patients in nyHA class iii and iv 
had higher galectin-3 levels (P  0.001). BnP and 
nT-proBnP levels were also higher when galectin-3   
levels were higher (P for trend 0.087 and  0.001, 
respectively); however, absolute differences in BnP 
and nT-proBnP were rather small—patients in the 
lowest quartile of galectin-3 had a median BnP of 
339 pg/ml and in the highest quartile 518 pg/ml. 
Patients with higher galectin-3 more often had dia-
betes and atrial fibrillation (P  0.01). Treatment 
was comparable in all quartiles, except that patients 
in  the  highest  quartile  less  often  received  ACe 
inhibitors (P  0.002).
Galectin-3 and outcome
Primary  outcome.  in  a  period  of  18  months,  248 
patients reached the primary outcome (164 deaths 
and  84  rehospitalizations  due  to  worsening  Hf). 
Adjusted Cox regression curves for quartiles of galec-
tin-3 are displayed in figure 1. We conducted uni-
variable analysis using patients in the lowest quartile 
of galectin-3 levels as a reference group (HR for the 
primary outcome set to 1.00). Compared to the ref-
erence group, patients in the second quartile had a 
hazard ratio (HR) of 1.98 (95% confidence intervals 
(Ci) 1.29–3.02; P  0.0016) for developing the pri-
mary outcome, patients in the third quartile a HR of 
2.66 (95% Ci 1.76–4.03; P  0.001), and patients 
in the fourth quartile a HR of 3.34 (95% Ci 2.23–
5.01; P  0.001). in Table ii, it is shown that correc-
tion for age, gender, and BnP only marginally altered 
the  predictive  power  of  galectin-3.  Correction  for 
egfR resulted in some loss, albeit very small, of pre-
dictive power of galectin-3, suggesting that some of 
the prognostic power of galectin-3 may be mediated 
via renal function. Correction for diabetes mellitus 
modestly mitigated the prognostic value of galectin-3. 
However, after correction for lvef, plasma galec-
tin-3 levels no longer statistically predicted the pri-
mary outcome. The interaction between lvef and 
galectin-3 is described in the next paragraph.
Secondary outcomes: all-cause mortality and hospital-
ization  due  to  HF . We  separately  analyzed  the  indi-
vidual elements of the primary end-point: 164 deaths 
(all-cause mortality) and 145 hospitalizations due to 
worsening Hf (this number exceeds the number of 
hospitalizations (n  84) of the primary outcome, as 
some patients were hospitalized several times). in the 
reference group (quartile 1), 34/148 patients experi-
enced the primary outcome (23 deaths, 11 hospitali  za-
tions); in the 2nd quartile, 75/148 patients experi  enced 
the primary outcome (35 deaths, 40 hospitalizations); 
in the 3rd quartile, 94/148 patients experienced the 
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galectin-3 predicts mortality after correction for age, 
gender, BnP, and egfR. of note, the predictive 
value of galectin-3 was markedly less after correction 
for lvef. The adjusted Cox regression curves for 
death and hospitalization due to Hf, according to 
quartiles of galectin-3, are displayed in supplementary 
figures 1 and 2.
Interaction between LVEF and prognostic value  
of galectin-3
We tested if lvef has an interaction with the predic-
tive value of plasma galectin-3. There was a statisti-
cally significant interaction between depressed lvef 
(40%) and preserved lvef (40%) and the pre-
dictive value of plasma galectin-3 levels (P  0.047). 
This interaction is graphically depicted in figure 2. 
This  figure  shows  that  an  identical  increase  in 
plasma galectin-3 levels represents a much stronger 
incremental risk for experiencing the primary out-
come in patients with HfPef in comparison with 
patients with HfRef (P  0.001). However, abso-
lute galectin-3 levels did not differ between patients 
with HfPef and HfRef (supplementary Table ii). 
This table also shows the other characteristics of both 
groups: patients with HfPef (n  114) were older, 
Table i. Base-line parameters according to the plasma galectin-3 levels.
Quartiles of galectin-3 (ng/ml)
variables
Quartile 1  
(5.0–15.2)
Quartile 2  
(15.2–20.0)
Quartile 3  
(20.0–25.9)
Quartile 4  
(25.9–66.6) P-value
n 148 148 148 148
Age (years) 66  11 70  11 72  11 76  9 0.001
gender (% male) 69 64 62 52 0.023
nyHA (%, ii / iii / iv) 61/38/1 51/48/1 45/51/4 30/63/8 0.001
Bmi (kg/m2) 27  5 28  5 27  5 28  7 0.56
lvef (%) 30  13 34  16 32  15 34  13 0.093
% patients lvef  40% 18 28 23 26 0.26
egfR (ml/min/1.73 m2) 67  17 61  18 50  16 37  15 0.001
Hb (g/dl) 14.0  1.9 13.3  1.9 13.0  2.0 12.5  2.0 0.001
BnP (pg/ml) (median; iQR)   339 (173–780)   457 (190–781)   488 (244–1120)   518 (229–1240) 0.001
nT-proBnP (pg/ml) (median; iQR) 1767 (1048–3464) 2386 (1283–4666) 3051 (1480–6652) 4302 (1664–11640) 0.001
medical history (%)
Hypertension 39 41 45 49 0.33
myocardial infarction 38 39 42 43 0.74
diabetes 19 29 37 35 0.004
Atrial fibrillation 35 41 49 57 0.001
CoPd 22 28 26 36 0.048
CvA 7 12 9 13 0.35
medication (%)
ACe inhibitors 79 72 78 61 0.002
ARB 9 16 12 7 0.10
Beta-blocker 72 69 66 62 0.28
diuretics 95 95 97 97 0.55
nyHA  new york Heart Association; Bmi  body mass index; lvef  left ventricular ejection fraction; egfR  estimated glomerular 
filtration rate; Hb  hemoglobin; BnP  brain natriuretic peptide; nT-proBnP  nT-pro-brain natriuretic peptide; CoPd  chronic 
obstructive pulmonary disease; CvA  cerebrovascular attack; ACe  angiotensin-converting enzyme; ARB  angiotensin receptor 
blockers.
figure 1. Adjusted Cox regression curves for quartiles of plasma 
galectin-3 showing the cumulative risk for the combined end-point 
all-cause mortality and hospitalization for Hf.
and in the 4th quartile, 106/148 patients experienced 
the primary outcome (64 deaths, 42 hospitaliza-
tions). This subanalysis lacks power to provide sig-
nificant differences in the secondary end-points after 
multiple correction (supplementary  Table i), although 64  R. A. de Boer et al. 
were more often female, and had more often a history 
of hypertension, while plasma BnP was lower.
Relation between galectin-3 and inflammatory 
cytokines (Table III and Table IV)
The cytokines vegf, il-6, and CRP had a signifi-
cant  positive  correlation  with  plasma  galectin-3 
levels, although correlation coefficients were weak. 
To investigate if galectin-3 may operate in inflamma-
tory response, we added the inflammatory cytokines 
to the multivariable model. none of the cytokines 
modulated the predictive power of galectin-3 on 
the primary outcome, although after correction of   
the full panel of cytokines the prognostic power of 
galectin-3 no longer reached statistical significance 
(P  0.083) (Table iv).
Comparison of galectin-3 with BNP as a biomarker  
in HF (Figure 3)
We  designed  (age-  and  gender-adjusted)  receiver-
operating characteristic (RoC) curves to characterize 
further the value of galectin-3 in predicting the pri-
mary outcome. The RoC analysis of galectin-3 for 
the prediction of the primary outcome showed an 
area under the curve (AuC) of 0.67 (P  0.004), 
while the AuC of BnP was 0.65 (P  0.001). The 
combination of both galectin-3 and BnP was 0.69 
(P  0.05 versus BnP or galectin-3 alone) (figure 3). 
similar findings were observed with C-statistics using 
the bootstrap technique (data not shown).
Value of repeated galectin-3 measurements (Figure 4)
overall,  plasma  galectin-3  levels  were  very  stable 
over a 6-month time period (data not shown). dif-
ferences over time in galectin-3 levels did not affect 
the power of base-line galectin-3 to predict outcome: 
after correcting the HR of ‘base-line galectin-3’ for 
the  ‘6-month  galectin-3’,  base-line  galectin-3  still 
powerfully predicted outcome (after correction for 
‘6-month galectin-3 levels alone’: P  0.001; or in 
combination  with  age,  gender,  BnP,  and  egfR:   
P  0.003). furthermore, we designed combined 
RoC  curves  with  both  base-line  galectin-3  and 
6-month galectin-3, in order to assess if serial mea-
surement of galectin-3 would yield superior predic-
tive value compared to one single measurement at 
base-line. The RoC analysis for base-line galectin-3 
for the prediction of the primary outcome showed 
an AuC  of  0.67  (P    0.004),  while  the AuC  of 
6-month galectin-3 was 0.66 (P  0.04). The com-
bination of both was 0.67 (P  ns versus base-line 
galectin-3 or 6-month galectin-3).
Discussion
This is the largest study thus far in Hf evaluating the 
predictive value of base-line plasma galectin-3 levels. 
We show that galectin-3 has independent prognostic 
value,  even  after  correction  for  established  risk   
factors  for  poor  outcome  in  Hf,  including  age,   
sex, BnP, renal function, and diabetes mellitus. in 
addition, we found an interaction with lvef and 
plasma galectin-3 and report here that the prognostic 
Table ii. Primary outcome: death or admission for heart failure: doubling of galectin-3.
variable Hazard ratio (95% Ci) P value
galectin-3 (doubling) 1.97 (1.62–2.42) 0.001
Adjusted for age (continuous), gender 1.90 (1.54–2.34) 0.001
Adjusted for age (continuous), gender, BnP 1.77 (1.42–2.20) 0.001
Adjusted for age (continuous), gender, BnP, egfR 1.43 (1.11–1.85) 0.006
Adjusted for age (continuous), gender, BnP, egfR, diabetes 1.38 (1.07–1.78) 0.015
Adjusted for age (continuous), gender, BnP, egfR, diabetes, lvefa 1.30 (0.97–1.74) 0.074
interaction with lvefb 0.047
aContinuous.
bReduced lvef ( 40%) versus preserved lvef ( 40%).
Abbreviations as in Table i.
figure 2. graphical depiction of the risk estimates for experiencing 
the primary outcome in patients with HfPef and HfRef with 
increasing levels of plasma galectin-3. The distribution of (log-
transformed) galectin-3 is depicted in the background in brown 
bars.  A  similar  increase  in  galectin-3  causes  a  much  more 
pronounced increase in risk in patients with HfPef compared 
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importance of plasma galectin-3 levels appears to be 
much stronger in the subset of Hf patients with pre-
served  lvef,  in  comparison  to  Hf  patients  with 
reduced  lvef.  finally,  base-line  galectin-3  levels 
seem to suffice to predict outcome, as serial sam-
pling did not increase the prognostic yield in our 
analysis.
galectin-3 has recently been proposed as a useful 
biomarker  involved  in  the  pathophysiology  of  Hf 
(2).  galectin-3  is  widely  distributed  throughout 
the body, including expression in heart, brain, and 
vessels  (3).  specifically,  secretion  of  galectin-3  is 
associated with activation of fibroblasts and fibrosis 
(3). A rat model of Hf revealed that galectin-3 is 
the strongest regulated gene when compensated left 
ventricular  hypertrophy  was  compared  with  overt 
Hf (4). The pathophysiological role for galectin-3 in 
development and progression of Hf has been sup-
ported  by  several  other  experimental  models  of 
Hf, like interferon-g-induced murine chronic active 
myocarditis and cardiomyopathy (14), rat strepto-
zotocin-induced diabetic cardiomyopathy (15), and 
angiotensin ii-induced hypertension in rats (16).
evidence from animal experiments has been sup-
ported by observations in humans. galectin-3 was 
found to be significantly up-regulated in hypertro-
phied  hearts  of  patients  with  aortic  stenosis  (4). 
since galectin-3 levels can be reliably measured in 
plasma, several groups have explored the value of 
plasma galectin-3 as a biomarker in Hf. However, 
until now only limited data are available in human 
Hf.  our  cohort  is  substantially  larger  than  other 
published  studies  on  galectin-3:  van  kimmenade   
et al. (5) (acute Hf), lok et al. (6) (mild, chronic 
Hf), milting et al. (7) (end-stage Hf), and lin et al. 
(8)  (chronic  Hf);  and  the  CoACH  cohort  was 
characterized by a very high event rate: in the current 
subset of 592 Hf patients, 248 patients reached the 
primary end-point, and 164 died.
As previously observed (5,6), we found that the 
prognostic value of galectin-3 is independent from 
(nT-pro-) BnP levels. natriuretic peptides are ‘load-
ing markers’, which readily and strongly respond to 
ventricular stress, while galectin-3 levels is viewed as 
a  marker  of  interstitial  fibrosis,  less  responsive  to 
(un-)loading. in support of this theory, milting et al. 
(7)  showed  that  unloading  of  poorly  contractile 
hearts with assist devices causes a robust decrease in 
various neurohormones, including natriuretic peptides, 
but not galectin-3.
We  describe  for  the  first  time  that  repeated 
measurements of galectin-3 levels (we measured at 
base-line and after 6 months, although in a small 
subset of patients, 291 out of 592) do not seem to 
add to the prognostic value. on an individual level, we 
observed that galectin-3 levels did not change sub-
stantially. This differs substantially from published 
observations with natriuretic peptides, which suggest 
that repeated measurement may increase diagnostic 
and  prognostic  yield  and  may  be  used  to  guide 
therapy (17,18). Arguably, galectin-3 activation and 






















57.1 (21.0–126.1) 57.3 (33.6–125.5) 61.2 (29.1–139.4) 76.1 (32.6–185.1) 0.043 0.1164 (n  537) 0.0069
il-6 (pg/ml) 
(median; iQR)
10.2 (4.7–20.0) 11.5 (7.6–19.4) 12.0 (6.6–26.5) 15.4 (8.8–30.3) 0.001 0.1683 (n  547) 0.001
CRP (mg/l) 
(median; iQR)
  2.0 (0.5–3.9)   2.3 (1.0–4.1)   2.4 (0.9–6.5)   2.6 (1.3–6.1) 0.003 0.1354 (n  547) 0.0018
Tgf-b1 (ng/ml) 
(median; iQR)
46.6 (30.8–75.2) 50.7 (37.6–68.6) 51.4 (33.5–75.0) 51.0 (35.0–79.7) 0.172 0.0784 (n  571) 0.0611
akruskal–Wallis test for difference in medians across quartiles.
vegf  vascular endothelial growth factor; il-6  interleukin-6; CRP  C-reactive protein; Tgf-b1  transforming growth factor-b1; 
iQR  interquartile range (25th percentile to 75th percentile).
Table iv. Primary outcome: death or admission for heart failure: 
doubling of galectin-3; influence of cytokines.
variable
Hazard ratio 
(95% Ci) P value
galectin-3 (doubling), adjusted for 
age (continuous), gender, BnP, 
egfR, diabetes (model 1)
1.38 (1.07–1.78) 0.015
model 1  CRP 1.36 (1.04–1.78) 0.026
model 1  il-6 1.32 (1.01–1.71) 0.041
model 1  Tgf-b1 1.35 (1.05–1.75) 0.021
model 1  vegf 1.32 (1.02–1.72) 0.037
model 1  CRP, il-6, Tgf-b1, 
vegf
1.29 (0.97–1.71) 0.083
Abbreviations as in Tables i and iii.66  R. A. de Boer et al. 
deposition  in  the  matrix  is  an  irreversible  process 
and therefore less amenable to altered hemodynam-
ics or other treatments (including pharmacological 
and  nurse-lead  intervention,  like  in  the  CoACH 
trial). Possibly, specific anti-fibrotic treatment may 
negate the adverse effects of galectin-3 (16).
We furthermore evaluated if galectin-3 would have 
interaction with different pro-inflammatory cytokines, 
since  it  is  well  described  that  galectin-3  plays  a 
central role in the inflammatory response, specifi-
cally in T cells (19–21). We correlated galectin-3 with 
an array of cytokines, which have been strongly linked 
to outcome in Hf, like il-6 and CRP (22,23). over-
all, a significant trend was observed that with increas-
ing galectin-3 levels pro-inflammatory cyto  kine levels 
also rise (Table iii). When we correlated galectin-3 
levels with the individual cytokines, however, cor-
relation coefficients were weak. These data support 
the observation that galectin-3 may be involved in 
inflammation, also in Hf. We hypothesize that given 
the modest correlation with cytokines, galectin-3 
likely exerts its effects in Hf predominantly via other 
pathways.
one of the most striking observations is that the 
predictive value of galectin-3 appeared to be stronger 
in patients with Hf with preserved ejection fraction 
(HfPef). until now, all published data on the prog-
nostic value of plasma galectin-3 levels were obtained 
in patients with HfRef (2,24). We defined HfPef 
as  lvef    40%,  concurrent  with  the  CHARm   
trial (11); however, other cut-off points have been 
proposed,  like  45%  (1)  or  35%  (25).  Recently,  a 
subanalysis  from  the  PRide  trial  (5),  involving   
76 patients, showed that plasma galectin-3 strongly 
correlated  with  echocardiographic  measurements   
of diastolic function (9). HfPef is a very common 
entity with distinct features from HfRef (26,27). 
few data are available on the use of biomarkers to 
diagnose HfPef. natriuretic peptides may be useful 
in this respect (28,29), but data are limited and by 
no means definite. Current guidelines (27) advocate 
the  use  of  natriuretic  peptides  in  the  diagnostic 
work-up, but no other biomarkers are mentioned.
We  observe  an  interesting  interaction  between 
lvef and galectin-3. When we graphically explored 
the predictive value of galectin-3 in the patients with 
HfPef versus HfRef (figure 2) we found that an 
identical rise in galectin-3 levels is associated with a 
much stronger increase in the risk for reaching the 
primary  end-point  in  patients  with  HfPef  (while 
average plasma galectin-3 levels did not differ sub-
stantially between patients with HfRef and HfPef). 
in other words, in the current cohort, specifically in 
patients with HfPef, increased galectin-3 levels are 
associated with worse prognosis. from the pathophys-
iology of HfPef (26,27), which is characterized by 
hypertrophy, matrix apposition, and myocardial stiff-
ening,  it  comes  natural  that  a  matrix  and  fibrosis 
marker like galectin-3 may be an important prognos-
tic  marker.  generally,  HfPef  is  more  common   
in elderly, female patients and associated with more 
frequent  co-morbidities  such  as  hypertension  and   
diabetes  (26,27),  which  we  confirm  in  our  study 
(supplementary Table ii). Previous observations (30) 
have  indicated  that  other  matrix  proteins  are  also   
useful in this respect. Confirmation is needed in inde-
pendent cohorts with HfPef patients, but we postu-
late  that  galectin-3  might  be  a  particularly  useful 
biomarker  in  HfPef.  of  note,  also  in  HfRef 
patients, increased levels of galectin-3 were associated 
with worse outcome in the CoACH cohort, so that 
our current finding does not negate previous reports.
figure  3.  Combined  receiver-operating  characteristic  (RoC) 
curves  for  brain  natriuretic  peptide  (BnP)  and  galectin-3  for 
prediction of death or Hf readmission in patients with Hf after 
18 months of follow-up. The RoC analysis for BnP showed an 
area under the curve (AuC) of 0.65 (P  0.001); for galectin-3 
the AuC is 0.67 (P  0.004). The RoC analysis for the combina-
tion of BnP and galectin-3 shows an AuC of 0.69 (P  0.05 
versus BnP or galectin-3 alone).
figure  4.  Combined  receiver-operating  characteristic  (RoC) 
curves for the prediction of death or Hf readmission in patients 
with Hf after 18 months for galectin-3 levels at base-line and 
galectin-3  levels  at  6-month  follow-up. The  RoC  analysis  for 
galectin-3 levels at base-line showed an area under the curve (AuC) 
of 0.67 (P for predicting the death or Hf readmission: 0.004); 
the AuC for galectin-3 levels at 6 months is 0.66 (P  0.04).   
The RoC analysis for a combination of galectin-3 levels at base-
line and levels at 6 months follow-up showed an AuC of 0.67   
(P  ns versus galectin-3 at base-line alone).  Galectin-3 in heart failure   67
Limitations
Plasma galectin-3 levels could only be measured in 
the  subset  of  patients  for  whom  base-line  plasma 
levels were available, although the clinical character-
istics of this subset did not differ from the entire 
CoACH cohort. sampling was at time of discharge 
so at variable time points, and at different levels of 
recompensation. follow-up samples were available 
from a minority of the patients, which could have 
caused bias and decreases power with respect to the 
analysis of repeated galectin-3 sampling. We realize 
that the observation that galectin-3 may be particu-
larly important in patients with HfPef is limited by 
the small number of patients. The echocardiographic 
evaluation was not standardized to a protocol, and 
we have no other echo data than lvef. further-
more, new guidelines question the cut-off point of 
40% to distinguish between HfPef and HfRef. 
The findings should be regarded as exploratory and 
be  confirmed  in  independent  cohorts  of  patients 
with  Hf  due  to  HfPef.  finally,  this  analysis  is 
underpowered to make decisive conclusions on the 
secondary end-points.
conclusions
in this to date largest Hf cohort, we confirm that 
galectin-3  is  a  strong  and  independent  prognostic 
factor. inflammatory markers are positively correlated 
to galectin-3 levels. Repeated galectin-3 sampling has 
no incremental value over base-line sampling alone. 
finally, galectin-3 might be a promising biomarker 
in patients with HfPef which nowadays comprise 
about half of all Hf patients.
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supplemental Table i. secondary outcomes: All cause mortality (death) and admission for heart failure: doubling of galectin 3.
death (n  164)
Hospitalizations due to Heart 
failure (n  145)
variable
Hazard Ratio  
(95% Ci) P-value
Hazard Ratio  
(95% Ci) P-value
galectin 3 (doubling) 2.15 (1.67 – 2.76) 0.0001 1.76 (1.36 – 2.28) 0.0001
Adjusted for age (continuous), gender 2.01 (1.54 – 2.61) 0.0001 1.70 (1.30 – 2.22) 0.0001
Adjusted for age (continuous), gender, BnP 1.74 (1.32 – 2.29) 0.0001 1.65 (1.26 – 2.18) 0.0001
Adjusted for age (continuous), gender, BnP, egfR 1.42 (1.02 – 1.96) 0.036 1.26 (0.91 – 1.74) 0.162
Adjusted for age (continuous), gender, BnP, egfR, 
diabetes
1.38 (1.00 – 1.91) 0.051 1.19 (0.86 – 1.65) 0.282
Adjusted for age (continuous), gender, BnP, egfR, 
diabetes, lvef* 
1.21 (0.83 – 1.80) 0.320 1.00 (0.66 – 1.51) 0.991
interaction with lvef** 0.636 0.047
*continuous.
**reduced lvef (40%) versus preserved lvef (40%).
supplemental Table ii. Patients characteristics from patients with HfRef and HfPef.
variables HfRef lvef  40% HfPef lvef  40%
n 368 114
Age (years)  69  12   74  10
gender (% male) 66 50
nyHA (%,  ii / iii / iv) 42/55/4 53/43/4
Bmi (kg/m2) 26  5 28  6
lvef (%) 26  8 53  8
egfR (ml/min/1.73m2)   55  20   53  21
Hb (g/dl) 13.5  1.9 12.6  2.2
BnP (pg/ml) (median; iQR)  511 (232 – 1110) 310 (152 – 605)
nT-proBnP (pg/ml) (median; iQR)  3045 (1597 – 7278) 1898 (839 – 3827)
galectin-3 (ng/ml) (median; iQR) 19.9 (14.8 – 25.7)  20.2 (16.0 – 26.0)
medical history (%)
   Hypertension 40 51
   myocardial infarction 44 30
   diabetes 28 29
   Atrial fibrillation 42 54
   CoPd 27 31
   CvA 11 10
medication (%)
   ACe inhibitors 77 58
   ARB 10 16
   Beta-blocker 72 60
   diuretics 96 95
1supplementary  figure  1.  Adjusted  cox  regression  curves  for 
quartiles of plasma galectin 3 showing the cumulative risk for all 
cause mortality.
supplementary  figure  2.  Adjusted  cox  regression  curves  for 
quartiles of plasma galectin 3 showing the cumulative risk for 
rehospitalization due to worsening Hf.
2